Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTKNASDAQ:PCVXNASDAQ:RYTMNASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$32.48-1.7%$40.42$31.70▼$68.44$3.87B0.811.67 million shs2.26 million shsPCVXVaxcyte$31.45+8.4%$48.25$27.66▼$121.06$4.06B1.271.30 million shs3.17 million shsRYTMRhythm Pharmaceuticals$60.72-6.0%$56.70$35.17▼$68.58$3.86B2.36545,721 shs1.08 million shsSNDXSyndax Pharmaceuticals$11.01+10.2%$12.65$9.66▼$25.07$947.34M0.821.68 million shs3.61 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics-2.95%-22.88%-8.20%-28.44%-49.39%PCVXVaxcyte-0.84%-19.10%-10.81%-67.43%-57.06%RYTMRhythm Pharmaceuticals+2.77%-1.14%+17.26%+7.39%+63.77%SNDXSyndax Pharmaceuticals-6.11%-29.40%-9.26%-36.85%-56.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTKCytokinetics4.1021 of 5 stars4.42.00.04.62.50.80.0PCVXVaxcyte2.8216 of 5 stars4.61.00.00.02.82.50.0RYTMRhythm Pharmaceuticals3.6211 of 5 stars3.51.00.04.32.70.80.6SNDXSyndax Pharmaceuticals4.02 of 5 stars4.51.00.04.43.20.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.89Moderate Buy$76.29134.90% UpsidePCVXVaxcyte 3.10Buy$136.50334.02% UpsideRYTMRhythm Pharmaceuticals 3.00Buy$75.3824.15% UpsideSNDXSyndax Pharmaceuticals 2.91Moderate Buy$35.91226.15% UpsideCurrent Analyst Ratings BreakdownLatest SNDX, PCVX, CYTK, and RYTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.005/7/2025CYTKCytokineticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$82.00 ➝ $80.005/7/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$86.00 ➝ $80.005/7/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$66.00 ➝ $72.005/6/2025SNDXSyndax PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$16.00 ➝ $17.005/6/2025SNDXSyndax PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.005/2/2025CYTKCytokineticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$47.00 ➝ $41.005/2/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.004/24/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$55.004/22/2025PCVXVaxcyteCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight4/21/2025CYTKCytokineticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$120.00 ➝ $120.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$18.47M209.55N/AN/A($3.94) per share-8.24PCVXVaxcyteN/AN/AN/AN/A$13.04 per shareN/ARYTMRhythm Pharmaceuticals$130.13M29.68N/AN/A$2.87 per share21.16SNDXSyndax Pharmaceuticals$23.68M40.01N/AN/A$6.53 per share1.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$526.24M-$5.26N/AN/AN/A-17,906.25%N/A-50.21%N/APCVXVaxcyte-$402.27M-$3.80N/AN/AN/AN/A-23.53%-22.20%5/14/2025 (Estimated)RYTMRhythm Pharmaceuticals-$184.68M-$2.81N/AN/AN/A-230.07%-367.36%-77.47%N/ASNDXSyndax Pharmaceuticals-$209.36M-$3.86N/AN/AN/AN/A-64.34%-57.72%N/ALatest SNDX, PCVX, CYTK, and RYTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PCVXVaxcyte-$1.02-$1.04-$0.02-$1.04N/AN/A5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million5/6/2025Q1 2025CYTKCytokinetics-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million5/5/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 million3/3/2025Q4 2024SNDXSyndax Pharmaceuticals-$0.31-$1.10-$0.79-$1.10$86.32 million$7.68 million2/27/2025Q4 2024CYTKCytokinetics-$1.29-$1.26+$0.03-$1.26$14.26 million$16.93 million2/26/2025Q4 2024RYTMRhythm Pharmaceuticals-$0.69-$0.72-$0.03-$0.72$38.48 million$41.83 million2/25/2025Q4 2024PCVXVaxcyte-$1.16-$1.02+$0.14-$1.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokinetics5.939.289.28PCVXVaxcyteN/A17.8817.88RYTMRhythm PharmaceuticalsN/A3.493.34SNDXSyndax PharmaceuticalsN/A6.996.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/APCVXVaxcyte96.78%RYTMRhythm PharmaceuticalsN/ASNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCYTKCytokinetics2.70%PCVXVaxcyte3.10%RYTMRhythm Pharmaceuticals5.60%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250119.19 million114.00 millionOptionablePCVXVaxcyte160129.00 million120.77 millionOptionableRYTMRhythm Pharmaceuticals14063.60 million58.02 millionOptionableSNDXSyndax Pharmaceuticals11086.04 million81.86 millionOptionableSNDX, PCVX, CYTK, and RYTM HeadlinesRecent News About These CompaniesSyndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $17.00May 8 at 12:35 PM | marketbeat.comSyndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at GuggenheimMay 8 at 10:36 AM | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Announces Earnings Results, Beats Estimates By $0.26 EPSMay 8 at 10:11 AM | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Position Increased by Crestline Management LPMay 8 at 7:43 AM | marketbeat.comSyndax Announces Participation in May Investor ConferencesMay 8 at 7:00 AM | globenewswire.comMarshall Wace LLP Has $167,000 Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 8 at 3:36 AM | marketbeat.comSyndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal BloodMay 7 at 4:01 PM | globenewswire.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2025 Earnings Call TranscriptMay 7 at 11:44 AM | msn.comSyndax Pharmaceuticals (NASDAQ:SNDX) Rating Increased to Sell at StockNews.comMay 7 at 4:31 AM | americanbankingnews.comWhy Syndax Pharmaceuticals, Inc.’s (SNDX) Stock Is Down 16.84%May 6 at 8:42 PM | aaii.comAvidity Partners Management LP Trims Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 6 at 7:39 AM | marketbeat.comAlgert Global LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 6 at 5:41 AM | marketbeat.comSyndax Pharmaceuticals, Inc. (SNDX) Q1 2025 Earnings Call TranscriptMay 5 at 11:30 PM | seekingalpha.comSyndax Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 5 at 11:18 PM | seekingalpha.comSyndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue EstimatesMay 5 at 6:10 PM | zacks.comSyndax Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 5 at 4:01 PM | globenewswire.comSyndax Pharmaceuticals (SNDX) Projected to Post Earnings on TuesdayMay 5 at 2:47 AM | americanbankingnews.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 4, 2025 | marketbeat.comSyndax Pharmaceuticals Inc (SNDX) Q1 2025: Everything You Need To Know Ahead Of EarningsMay 3, 2025 | finance.yahoo.comSyndax Pharmaceuticals Q1 2025 Earnings PreviewMay 2, 2025 | msn.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNDX, PCVX, CYTK, and RYTM Company DescriptionsCytokinetics NASDAQ:CYTK$32.48 -0.56 (-1.69%) Closing price 04:00 PM EasternExtended Trading$32.65 +0.17 (+0.53%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Vaxcyte NASDAQ:PCVX$31.45 +2.45 (+8.45%) Closing price 04:00 PM EasternExtended Trading$31.74 +0.30 (+0.94%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Rhythm Pharmaceuticals NASDAQ:RYTM$60.72 -3.91 (-6.05%) Closing price 04:00 PM EasternExtended Trading$60.72 0.00 (0.00%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Syndax Pharmaceuticals NASDAQ:SNDX$11.01 +1.02 (+10.21%) Closing price 04:00 PM EasternExtended Trading$10.70 -0.31 (-2.77%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
